Meghan Zubradt is a Senior Director of Global Business Development at GSK. In this role, she is responsible for leading and executing transactions for high-value asset deals across therapeutic areas. Most recently, Meghan successfully led GSK’s acquisition of a novel molecule in development for autoimmune disease. Prior to GSK, Meghan was part of the business development team at Johnson & Johnson where she supported oncology and immunology. Meghan has held diverse roles across alliance management, search and evaluation, portfolio management, and investor relations within academia, early biotech, and large pharma. She has a B.S. in Biology from Brown University and a PhD from the University of California, San Francisco.